Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Therapy of TDF and Peg-IFN alpha-2a in HBV Related Hepatic Fibrosis
NCT03957629Unknown
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Nov 2019
- Primary completion
- Jul 2021
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Randomised, open-label trial of peginterferon alfa-2a in hepatitis B (HBV) and Liver Fibrosis (LF) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: Ratio of regression of fibrosis at 96 weeks. Status: unknown.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis B (HBV)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT03957629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03957629.